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Disclaimer 
 
 
Certain commercial equipment, instruments, and materials are identified in 
this report to specify adequately the experimental procedure. In no case does such identification imply 
recommendation or endorsement by the European Commission, nor does it imply that the material or 
equipment is necessarily the best available for the purpose. 
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Abstract 
The production and certification of ERM-DA472/IFCC, a new reference material certified for 
C-reactive protein (CRP), is described.  
Serum was produced from blood collected in 6 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low.  
The serum was processed in 5 batches, and then pooled, spiked with β2 microglobulin (B2M) 
and CRP and filled into ampoules (approximately 1 mL serum per ampoule). The serum was 
stored at -70 °C. It was verified that the material was homogenous and stable. 
ERM-DA472/IFCC was characterised using the reference material ERM-DA470 as calibrant. 
This was achieved using a value transfer protocol that can be considered as a reference 
procedure. The principles used to measure the CRP concentration were 
immunonephelometry and immunoturbidimetry. The measurements were performed with 
different platform/reagent combinations (Abbott Architect, Beckman Immage, BN II, different 
Hitachi instruments, and Olympus AU640). In total 8 laboratories participated in the value 
assignment. The certified CRP mass concentration is 41.8 mg/L, the expanded uncertainty (k 
= 2) 2.5 mg/L. 
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 GLOSSARY 
ANOVA  analysis of variance 
b  slope in the equation of linear regression y = a + bx 
Bit  unit of the analog-to-digital converter of the light detector 
c  mass concentration c = m / V (mass / volume), the unit is g/L 
B2M  β2 microglobulin 
C3c  complement 3c 
C3  complement 3 
CASO  Casein Soy  
CRM  Certified Reference Material 
CRP  C-reactive protein 
ERM  European Reference Material 
HBV  hepatitis B virus 
HBsAg  hepatitis B surface antigen 
HCV  hepatitis C virus 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  human immunodeficiency virus 
IFCC  International Federation of Clinical Chemistry and Laboratory Medicine 
IRMM  Institute for Reference Materials and Measurements 
IU  International Unit 
IVD  In Vitro Diagnostics 
k  coverage factor 
KIU  Kallikrein Inhibitor Unit 
m  mass 
MSbb  mean sum of squares between bottles 
MSwb  mean sum of squares within bottles 
n  number of replicates 
ND  not detectable 
PAGE  polyacrylamide gel electrophoresis 
RM  reference material 
RF  rheumatoid factor 
R2  correlation coefficient of the linear regression 
s  standard deviation 
sbb  standard deviation between bottles 
sbb, rel   relative sbb 
SDS  sodium dodecyl sulfate 
swb  standard deviation within bottles 
T  target material 
TF  transfer factor 
TRIS  tris(hydroxymethyl)aminomethane 
U  expanded uncertainty 
ub  standard uncertainty of the slope b 
ubb, rel relative standard uncertainty related to the between-bottle heterogeneity 
u*bb standard uncertainty related to the between-bottle heterogeneity that can be 
hidden by the method repeatability 
u*bb, rel relative u*bb 
uc, rel  combined relative standard uncertainty 
ucal, rel  relative standard uncertainty of the calibrant 
uchar, rel  relative standard uncertainty related to the characterisation 
ults, rel relative standard uncertainty related to the long-term stability of the material 
usts, rel  relative standard uncertainty related to the short-term stability of the material
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1 Introduction and design of the project 
1.1 Background: need for the CRM 
C-reactive protein (CRP) is an important analyte in clinical chemistry. It is a very sensitive 
marker of inflammation and tissue damage [1]. Routine clinical uses of CRP results include 
the diagnosis of bacterial and viral infections and the assessment of disease activity in 
inflammatory conditions like rheumatoid arthritis.  
CRP was originally discovered by Tillett and Francis in 1930 as a substance in the serum of 
patients with acute inflammation that had the capacity to precipitate the C polysaccharide of 
pneumococcus [2]. In the blood of healthy young adult volunteer blood donors, the median 
mass concentration of CRP is 0.8 mg/L, the 90th centile is 3.0 mg/L, and the 99th centile is 
10 mg/L. Following an acute-phase stimulus, values may increase to more than 500 mg/L [1]. 
The finding that modest but persistently increased values are associated with a long-term 
risk for coronary heart disease [3] has led to the development of assays specifically designed 
to measure relatively low concentrations of CRP. These assays are often called high 
sensitivity CRP (hs CRP) assays. 
The immunoassays used for CRP measurements are capable of a high degree of analytical 
sensitivity and selectivity, and are convenient in a clinical setting because they give fast 
results. They are based on the fact that when antigens (serum proteins) and specific 
antibodies are brought together they form complexes or aggregates that scatter incident light. 
The scattering of the light is measured by turbidimetry (measuring the reduction of light 
passing through a reaction mixture) or nephelometry (measuring the light scattered by a 
reaction mixture). The signal is dependent on a large number of factors such as antibody 
specificity, reaction kinetics and equilibria, multimeric state of the proteins, complex matrix 
effects, etc. The quantification with immunoassays is therefore entirely dependent on the 
comparison of the results with those obtained with a calibrant [4].  
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) 
requires traceability of the assigned values of calibrants and control materials to reference 
measurement procedures and/or reference materials of higher order. 
In 1989 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
began the processing, characterisation, and calibration of a matrix reference material for 
human serum proteins. In 1993 the Bureau Communautaire de Référence released the 
resulting CRM 470 (later re-evaluated and renamed to ERM-DA470), certified for 15 proteins 
[5]. The protein concentration measurements done for the value assignment of CRP in ERM-
DA470 were calibrated with the 1st International Standard CRP 85/506.  
After the release of ERM-DA470 IVD manufacturers began referencing their calibrants and 
controls to the material, and the between-laboratory variation for assays of serum proteins 
became substantially lower for most of the proteins certified in ERM-DA470 [6], [7]. 
The present material has been produced to replace ERM-DA470 as far as CRP is 
concerned. The material ERM-DA470k/IFCC (available from IRMM) replaces ERM-DA470 
for 12 other proteins, but it was not suited for the certification of CRP because of a bias in the 
CRP values introduced by the lyophilisation process. 
1.2 Choice of the material 
The requirements for a material to be used as a reference material for serum protein 
immunoassays are, next to requirements for homogeneity, stability and metrological 
traceability: 
 the material should behave like fresh patient samples (commutability) 
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 the concentration of the proteins in the final material should be high enough so that 
dilutions of the material can cover the relevant part of the measurement interval of the 
assays 
 the material should be optically clear. This property is important, as most clinical 
immunoassays use optical measurement methods. This means that the material must 
have a low content of lipids and lipoproteins 
 there must be continuity of the measurement results from assays calibrated against 
consecutive reference materials. This is an important issue in clinical chemistry, as 
the use of reference ranges and decision limits requires that measurement results are 
comparable over longer time scales 
Therefore it was decided to produce the new material according to procedures similar to 
those applied for ERM-DA470. However, the ERM-DA472/IFCC material for CRP was stored 
liquid frozen instead of lyophilised, ensuring that the CRP is present in its native pentameric 
state. 
1.3 Design of the project 
The material used for this reference material is the same as that used for producing ERM-
DA470k/IFCC [5]. The processing is the same up to the point of either filling in vials (ERM-
DA470k/IFCC) or ampouling (this material). 
Serum was produced from blood collected in 6 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low.  
The serum was processed in 5 batches, and then pooled, spiked with B2M and CRP. The 
serum was filled in ampoules, which were afterwards stored at -70 °C. 
The material was characterised by using the reference material (ERM-DA470) as calibrant. 
This was achieved using a value transfer protocol that can be considered as a reference 
procedure [8]. In the so called closed value transfer procedure 6 dilutions of the calibrant 
(ERM-DA470) and 6 dilutions of ERM-DA472/IFCC are measured against the usual 
instrument calibrant, and the concentration of the target material is determined from the ratio 
of the slopes of the regression lines (concentration versus dilution). In the open value 
transfer procedure, ERM-DA470 is used as a calibrant in the instrument, and the 6 dilutions 
of the target material are measured directly against different dilutions of that calibrant. 
The techniques used to measure the protein concentrations were nephelometry and 
turbidimetry. The measurements were performed with different platforms (i.e. instruments; 
Abbott Architect, Beckman Immage, BN II, different Hitachi instruments, Olympus AU640, 
Roche Integra) and reagents. In total 8 laboratories participated in the value assignment, 6 
using open value transfer procedures and 2 using closed value transfer. The majority of the 
characterisation measurements were either done under an ISO/IEC 17025 accreditation or 
within the scope of an ISO 13485 quality system. Documented evidence of the technical 
competence and applied document control was obtained from the remaining laboratories. 
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2 List of participants 
Provision of serum and proteins 
- Asahikawa Medical College, Asahikawa (JP) 
- Azienda Ospidaliera Policlinico Modena, Modena (IT) 
- Blutspendedienst SRK Bern, Bern (CH) 
- Centre de Transfusion Sanguine Liège, Service du Sang de la Croix-Rouge de Belgique, 
Liege (BE) (accred. ISO 15189 BELAC 331-MED) 
- Centre for Amyloidosis and Acute Phase Protein, UCL Division of Medicine, London (GB) 
- Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) 
- Hralec Králové University Hospital, Hralec Králové (CZ) 
- Universita degli Studi di Pavia, Pavia (IT) 
Characterisation and processing of the serum 
- Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 13485 
TÜV Rheinland Product Safety GmbH SX 60014517 0001)  
- Universitetssjukhuset I Lund, Lund (SE) (accred. ISO/IEC 17025 SWEDAC 1424) 
Stability and homogeneity studies 
- DAKO Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
- Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 
13485TÜV Rheinland Product Safety GmbH SX 60014517 0001) 
- Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (Accred. ISO Guide 34 BELAC 268-TEST) 
Characterisation 
- Abbott Diagnostics, Irving (US) (certified ISO 13485 UQA 0103128/B) 
- Beckman Coulter, Brea (US) (certified ISO 13485 NSAI MD 19.0779) 
- Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 13485 
TÜV Rheinland Product Safety GmbH SX 60014517 0001) 
- DAKO Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
- Kreiskliniken Altötting-Burghausen, Altötting (DE) 
- Nitto Boseki, Fukushima (JP) (certified ISO 13485 SGS GB06/68575) 
- Olympus Life and Materials Science, Clare (IE) (certified ISO 13485 TÜV Rheinland 
Product Safety GmbH  SX 60021010 0001) 
- Protein Reference Unit, St. Georges Hospital, London (GB) 
- Roche Diagnostics GmbH, Penzberg (DE) (certified ISO 13485 TÜV SÜD Q1N 07 08 
45096 003) 
Data analysis 
- Acomed Statistik, Leipzig (DE) 
- Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (Accred. ISO Guide 34 BELAC 268-TEST) 
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3 Processing 
3.1 Preparation of the serum 
The starting material for the reference material was the serum prepared from the blood of 
healthy donors, collected at 6 different blood collection centres (Table 1).  
Selection of the donors: Donors with clinical diagnoses of diabetes mellitus, jaundice, high 
blood pressure, heart, lung or kidney disease, pregnant women and top performance 
athletes were excluded. Donations with high cholesterol or triglyceride concentrations were 
rejected. Donations from people with hepatitis and human immunodeficiency virus (HIV) 
infections were excluded, as well as donors with clinical evidence of bacterial infections. 
Serum collection protocol: 400 – 500 mL whole blood was withdrawn from each donor, 
expected to give an average serum volume of 180 mL (140 – 220 mL). For donors from 
Japan the volume of blood withdrawn was between 200 and 300 mL.  
The following protocol was applied for preparing the serum: 
a) Pre-prandial blood (tourniquet used) (the blood collected in Germany was not strictly pre-
prandial, but a very stringent selection was made on the transparency of the serum). 
b) Collection into a dry bag or a polymer bottle, not containing any additives or 
anticoagulants (such as Baxter, Fenwal). 
c) Clotting at room temperature for 3 - 4 hours. 
d) Centrifugation of the bag in a centrifuge bucket or the bottle at 2200 g for 20 min 
e) Separation of the serum from the clot 
f) Freezing of the serum between -70 and -80 °C. 
g) Transport of the serum to the IRMM on dry ice, storage at -70 °C. The serum produced in 
the Czech Republic was stored for a few days at -30 °C before being shipped on dry ice. 
Table 1: Summary information on the collected serum. The parenthesised numbers indicate 
how many male and female donations are fulfilling the inclusion criteria. 
Collection centre  Donation period No. Male Female 
RF > 30 
IU/mL 
Monoclonal 
components 
Final 
No. 
Blutspendedienst 
SRK Bern AG (CH) 12/2006 80 78 (73) 2 (1) 3 3 74 
Hradec Králové 
University Hospital 
(CZ) 
11-
12/2006 80 64 (62)* 16 (16) 0 1 78 
Croix Rouge de 
Belgique, Liège (BE) 
10/2006 
to 
01/2007 
101 58 (57) 43 (42) 0 2 99 
Dade Behring 
Marburg GmbH (DE) 10/2006 60 46 (44) 14 (13) 3 0 57 
Asahikawa Medical 
College (JP) 
09/2006 
to 
01/2007 
 
26 14 (13) 12 (11) 2 0 24 
Policlinico Modena 
(IT) 
12/2006 
to 
02/2007 
60 46 (45) 14 (13) 2 0 58 
* one donation lost due to a leaking container 
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Tests of the serum: The blood collection centres tested each donation for HIV 1+2, HBV or 
HBsAg, and HCV. Monoclonal gammopathies were detected by gel electrophoresis. Six 
donations were discarded because of the presence of monoclonal components, and ten 
donations were discarded because their Rheumatoid Factor (RF) concentration was above 
30 IU/mL (Table 1). 390 donations, of which 96 originated from female donors, were fulfilling 
the inclusion criteria, and were released for further processing. 
3.2 Processing of the serum 
Overview of the procedure 
The processing procedure is summarised in Figure 1. It followed largely that used for CRM 
470 (ERM-DA470) [5]. The major differences were that after the delipidation step a 
diafiltration with a membrane with a cut-off of 10 kDa was used instead of a dialysis with 
membranes with a cut-off of 12-14 kDa, that no sodium azide was added to the serum before 
the pooling of the individual donations, and that the final sodium azide mass concentration 
was kept below 1 g/L. 
The serum donations from each collection centre were pooled and processed as collection 
centre pools.  Particulate matter and lipids were removed, and a uniform degree of 
'maturation' of the serum achieved. As the batch from Japan was small it was processed 
together with the serum from Belgium. The serum from different collection centres was then 
pooled, spiked with B2M and CRP and sterile filtrated after addition of preservatives (sodium 
azide, aprotinin and benzamidine hydrochloride), before the filling.  
 
 
 
Figure 1: Overview of the processing of the serum.  
Thawing+pooling 
Sodium azide added 
 State A 
Conversion of C3 to C3c 
Delipidation 
Diafiltration  
 State B 
Addition of HEPES, 
aprotinin, sodium azide, 
benzamidine 
hydrochloride 
Sterile filtration  
 State C 
Pooling 
Spiking 
Sterile filtration 
 
DE CH CZ BE JP IT 
Pool
Testing of spiking 
B2M commutability study 
Stability study  
Trial value assignment 
Pilot studies 
 
Filling 
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3.2.1 Preparation of pools per collection centre 
Donations fulfilling the criteria were processed as follows: 
• thawing overnight at 2 - 8 °C 
• determination of the volume of each donation 
• pooling of all accepted donations of the same collection centre 
• addition of sodium azide (Merck, Darmstadt, DE) to a final amount of substance 
concentration of 7.7 mmol/L (approximately 0.5 g/L) 
• removal of 1/8th of the volume of each pool for verification and testing purposes and 
storage in 50 mL plastic tubes at a temperature below -70 °C 
• removal of aliquots for the measurement of cholesterol, triglycerides, apolipoprotein 
A-I, apolipoprotein B, total protein (Biuret reaction) and for the concentration 
measurement and physicochemical analysis of selected proteins. 
 
The material is now in State A 
Conversion of C3 to C3c 
• adjustment of pH to 7.2 ± 0.1 with saturated 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (Calbiochem, Merck Biosciences, 
Schwalbach, DE) 
• addition of magnesium acetate tetrahydrate, final amount of substance concentration 
20 mmol/L (Merck, Darmstadt, DE) 
• adjustment of the solution to 37 °C  
• addition of Inulin (Sigma Aldrich, Milwaukee, US) to a final mass concentration of 
0.2 %  
• stirring for 2 hours at 37 °C. 
Delipidation with Aerosil 
• adjustment of the inulin-treated pool to pH 8.5 ± 0.1 with a saturated 
tris(hydroxymethyl)aminomethane (TRIS) solution (Sigma-Aldrich, Milwaukee, USA) 
• addition of sodium chloride (crystalline; Merck, Darmstadt, DE) to a final 
concentration of 50 g/L while stirring constantly 
• calculation of the required amount of Aerosil 200 (Degussa, Frankfurt, DE) based on 
the total protein concentration of the pool before the C3 conversion (430 mg 
aerosil / g total protein) 
• gradual addition of Aerosil while stirring and constantly monitoring and if necessary 
adjusting the pH to 8.5 ± 0.1 
• continued slow stirring for another 30 min 
• removal of Aerosil (Degussa, DE) and protein precipitates by centrifugation for 30 min 
at approximately 10000 g using 500 mL centrifugation bottles 
• determination of the total volume of the clear supernatant  
• determination of the concentrations of cholesterol, triglycerides and apolipoproteins 
A-I and B to verify the successful lipid removal. 
Sterile filtration and diafiltration 
• filtration of the supernatant using a 0.45 µm Sartobran P filter (Sartorius, Göttingen, 
DE) to remove small particles interfering with the following diafiltration  
• diafiltration (Centrasette with Omega membrane with a molecular weight cut-off of 
10000; Pall, Hauppauge, USA) using an isotonic sodium chloride solution to remove 
TRIS and Aerosil-derived free silica; this step combines buffer exchange and 
adjustment to the desired volume 
• removal of aliquots for the measurement of the total protein mass concentration and 
for the measurement and physicochemical analysis of selected proteins.  
 
Material is now in State B 
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Preservation and sterile filtration 
• adjustment of the pH with a saturated HEPES solution to 7.2 ± 0.1 
• addition of sodium azide to achieve a final amount of substance concentration of 14.6 
mmol/L (0.95 g/L) 
• addition of aprotinin (Trasylol 500000 KIU/L, Bayer, Leverkusen, DE) to achieve a 
final concentration of 80000 KIU/L  
• addition of benzamidine hydrochloride monohydrate (Merck, Darmstadt, DE) to a final 
amount of substance concentration of 1 mmol/L 
• sterile filtration using a Sartopore 2 filter (0.2 µm) (Sartorius, Göttingen, DE) 
• sterile removal of aliquots for the measurement of the total protein content and for the 
measurement and physicochemical analysis of selected proteins 
• sterile removal of 150 mL of the DE, CZ and CH pools; these aliquots were stored 
below -70 °C until processing of the pilot batches. 
The material is now in State C.  
Until their combination the collection centre pools were stored at temperatures below -70 °C. 
Protein concentration measurements: Throughout the processing, the mass concentrations 
of the proteins certified in ERM-DA470k/IFCC and CRP, as well as of apolipoprotein A-I and 
B were determined by immunonephelometry on a BN ProSpec or BN II System using 
reagents, standards and controls of Dade Behring Marburg GmbH.  
Total protein determination: Determination of total protein was done according to the Biuret 
method using pure human serum albumin (internal Dade Behring product) for calibration, 
solutions and chemicals were from Merck (Darmstadt, DE) or Sigma-Aldrich (Milwaukee, 
USA). 
Lipids: The cholesterol concentration was measured using the cholesterol CHOD-PAP Kit 
and triglycerides with the Triglycerides GPO Kit (Roche Diagnostics, Mannheim, DE). 
Blank signal: According to the specifications for the platform concerned an empty cuvette is 
considered adequately inserted and optically clear if the scattered light gives a signal 
between 20 and 600 Bit.  
Physicochemical structure of CRP: The integrity (oligomeric state, behaviour in terms of 
charge/size in electrophoretic mobility) of the main serum proteins during processing was 
verified using several methods: 
• 2-dimensional immunoelectrophoresis according to Clarke and Freeman [9] 
• native PAGE followed by western blotting (CRP only) 
• size exclusion chromatography followed by SDS PAGE and Western blotting (CRP 
only) 
• 2-dimensional electrophoresis.  
 
3.2.2 Preparation of the combined pool 
 
Preparation of CRP and B2M  
463 mL of a purified human CRP solution (CRP mass fraction 97 % of total protein; CRP 
mass concentration 3.88 g/L) was used. The material was stored below -70 °C and thawed in 
a water bath at 37 °C with occasional turning. Before spiking the pool, the CRP solution was 
gently mixed while avoiding any turbulence. The starting material for B2M was a lyophilised 
purified recombinant protein. 
 
Preparation of the final material 
• thawing of all 5 collection centre pools (2 to 3 days) 
• pooling  
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• sterile removal of aliquots for the measurement of B2M and CRP concentrations, and 
for the physicochemical analysis  
• preparation of the CRP solution as described 
• slow addition of the total amount of the CRP solution (463 mL) while constantly 
stirring 
• reconstitution of recombinant B2M in sterile water  
• addition of B2M to the pool to a final mass concentration of approximately 2.6 mg/L 
(total added 65 mg) 
• pH adjustment with saturated HEPES solution (pH 7.2 ± 0.1) 
• sterile filtration (0.2 µm) 
• sterile removal of aliquots for further analysis, including sterility testing 
The same combined pool was used for preparing the lyophilised ERM-DA470k/IFCC and the 
liquid frozen ERM-DA472/IFCC. 
3.2.3 Processing control 
Pools per collection centre 
Total protein concentration: In line with the protocol of the preparation of the original ERM-
DA470 only pools with a total protein concentration between 60 and 80 g/L were considered 
to qualify as starting material for processing, and the Aerosil treated pools should be 
adjusted to between 55 and 75 g/L. As shown in Table 2, the total protein mass 
concentration of the pools was between 69 and 77 g/L in State A and between 64 and 69 g/L 
in State C, i.e. within the defined tolerance limits. 
 
Table 2: Total protein mass concentration (Biuret method) of pools at different processing 
stages 
 State A State B State C 
Collection 
centre pool 
Total protein 
[g/L)] 
Total protein 
 [g/L] 
Total protein 
[g/L] 
DE 69.0 68.4 65.8 
CZ 72.0 68.1 69.2 
CH 77.3 67.7 68.8 
BE 69.9 
JP 73.7 
66.9 63.8 
IT 71.1 70.9 69.4 
Delipidation: The delipidation by the Aerosil treatment is considered successful when the 
relative mass concentrations of cholesterol and apolipoprotein B are reduced to 1 % of the 
concentration in the starting material. The relative mass concentrations for triglycerides and 
apolipoprotein A-I should be below 15 % and 20 % of the starting material, respectively. As 
shown in Table 3, these criteria were fulfilled for all collection centre pools. The reduction of 
the blank value obtained by measuring the signal of undiluted sample using a BN100 System 
also demonstrated the effective removal of lipoproteins (Table 4). 
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Table 3: Lipoproteins mass concentrations before processing and after Aerosil treatment1 
 State A State B 
Pool 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
DE 1627 1189 1555 806 ND 95.5 ND ND 
CZ 1788 2266 1565 931 ND 56.4 ND ND 
CH 1760 920 1715 874 11.5 95.5 ND ND 
BE 1903 767 1620 870 
JP 1875 1158 1595 783 
ND 8.3 ND ND 
IT 1846 725 1645 842 5.8 8.3 ND ND 
1 when the concentration is below the limit of detection this is marked by ND (not detectable) 
 
 
Table 4: Blank signal measured with a nephelometer before and after Aerosil treatment 
 Blank value [Bit] 
Pool State A State C 
DE 3497 55 
CZ 1992 75 
CH 3082 103 
BE 1553 
JP >2 
99 
IT 2498 101 
 
1 exceeds measuring interval (0-4096 Bit) 
 
Preparation of the combined pool 
Sterility test: The sterility of the material was verified by inoculating Casein Soy (CASO) Bean 
Digest Broth with the sterile filtrated pool, and streaking it out on CASO agar, Blood agar and 
McConkey agar (Institut für Medizinische Mikrobiologie und Krankenhaushygiene, University 
of Giessen and Marburg, Marburg, DE). No growth was observed on the selected media after 
five days, and the pool was released for filling. 
Blank values: The blank value for the final pool before sterile filtration was 93 Bit (detector 
values), after sterile filtration 84 Bit, and the material could thus be considered as optically 
clear.  
Mass density measurements: The mass density of ERM-DA472/IFCC and reconstituted 
ERM-DA470 were measured with an Anton Paar densitometer (Graz, AT), and found to be 
1.0236 and 1.0234 g/mL, respectively, at 20 °C. As the difference between the densities of 
the two materials is negligible compared to the uncertainty of the certified value no 
systematic density correction was applied to the transfer factors.  
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3.3 Filling and labelling 
The serum was ampouled at the IRMM. Approximately 1 mL serum was filled into 3 mL 
Duran glass ampoules using a Rota ampouling machine R 910 PA (Rota, Wehr, DE). The 
ampoules were first opened, filled, flushed with argon and flame sealed. During the filling, the 
bottle containing the serum was kept at low temperature in a tray filled with ice / water. Teflon 
tubing was used. The ampouling machine was adapted to minimise the formation of foam in 
the ampoules. After filling, the ampoules were kept at + 4 °C and labelled according to the 
filling order. Thereafter the material was frozen at -70 °C. 
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4 Homogeneity  
4.1 Between and within vial homogeneity 
The homogeneity of ERM-DA472/IFCC was verified by measuring CRP in 15 ampoules 
randomly selected from the whole batch. The CRP mass concentration was measured 6 
times in each ampoule using a BN ProSpec platform and Dade Behring reagents. 
Grubbs tests were performed to detect outlying individual values as well as averages 
measured for each vial. No outliers were detected at the 95 % confidence level. 
Regression analyses were used to evaluate potential drifts in values related to the analysis 
sequence or to the filling sequence. It was furthermore checked whether the data followed a 
normal or at least unimodal distribution using normal probability plots and histograms 
respectively. The individual data and the averages were normally distributed. A small but 
significant (at the 95 % confidence level) drift in function of the analytical sequence was 
detected, but not corrected for, as it was small compared to the overall uncertainty. 
One-way ANOVA statistics showed that there was no significant heterogeneity at the 95 % 
confidence level (F-test). The between bottle standard deviation (sbb) and the maximum 
standard uncertainty related to the inhomogeneity that can be hidden by the method 
repeatability (u*bb), were calculated using the formulas: 
 
 
       
(MSbb = mean sum of squares between bottles; MSwb = mean sum of squares within bottles; 
n = number of replicates; dfwb = degrees of freedom within bottles). The values were 
converted into relative uncertainties. 
The sbb, rel, which is the highest of the two values sbb, rel = 0.290 % and ubb, rel* = 0.274 %, was 
used as an estimate of the uncertainty related to inhomogeneity, and was included into the 
calculation of the overall uncertainty of the certified values (Section 7.1).  
4.2 Minimum sample intake for analysis 
The material forms a clear solution. Therefore it is not expected to have any relevant 
heterogeneity in the CRP concentration at sample intakes even below nL volumes. The 
sample intake of the homogeneity study on the material measured with a BN ProSpec 
platform was 20 μL. The standard deviation within a bottle (swb) is lower or equal to the 
expected method variability (data not given), so there is no indication of intrinsic 
heterogeneity at a sample intake of 20 μL.  
  
n
MSMSs wbbbbb
−= 4wb*bb 2
wbdfn
MSu ⋅=
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5 Stability 
Short and long-term stability studies were carried out using an isochronous set-up [10] that 
consists of the simultaneous analysis of samples from reference and test ampoules. For 
each study a defined set of ampoules was exposed for different periods of time to elevated 
temperatures and then brought back to the reference temperature. At the end of the study all 
ampoules were analysed for the concentrations of CRP within one analytical run, in triplicate. 
The data were analysed by determining the regression line for the CRP concentration in 
function of time [10]. 
5.1 Short-term stability 
A short-term stability study was performed in order to assess the possible effect of transport 
at different temperatures on the stability of the material. Test ampoules were kept for 0, 1, 2, 
and 4 weeks at -20, 4, 18 and 60 °C before being brought back to the reference temperature 
(-70 °C in the short term stability study). For each combination of time and temperature 2 
ampoules were analysed in triplicate. The CRP concentration was measured by turbidimetry 
using a Hitachi 917 measuring system and DAKO reagents.  
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Figure 2: Results of the short-term stability study. The trendline for the CRP concentration in 
function of storage time is shown for samples stored at -20 °C. 
Table 5: Short-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty after two weeks storage at the specified temperature (usts, rel) 
Temperature 
[°C] 
b 
[(mg/L)/week] |b/ub| 
usts, rel 
[%] 
-20 0.011 0.22 0.24 
4 0.061 0.13 0.24 
18 0.029 0.74 0.19 
60 -15.1 2.6 92 
For ampoules stored at -20, 4 and 18 °C there were 24 measurements, or 22 degrees of 
freedom for the linear regression. The slope of the CRP concentration in function of time is 
significantly different from 0 when the absolute value of slope b divided by its uncertainty ub 
(|b/ub|) is larger than t0.05, 22 = 2.07. When ampoules were kept at -20, 4, and 18 °C none of 
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the slopes was significantly different from 0. At 60 °C the solution became turbid with a 
precipitate within one week, and the CRP concentration dropped significantly (at a 95 % 
confidence level).  
From this study it was concluded that for the shipment (for maximum two weeks) of 
ampoules at temperatures at or below 4 °C the possible contribution of the transport to the 
uncertainty of the certified values is negligible compared to the overall uncertainty. For 
practical reasons the material will be shipped on dry ice.  
5.2 Long-term stability 
A 6 month stability study was performed in order to confirm the stability of the material upon 
storage at -70 and -20 °C. The reference temperature was at or below -150 °C (stored above 
liquid nitrogen). The test ampoules were kept for 0, 2, 4, and 6 months at -70 and -20 °C. For 
each combination of time and temperature 2 ampoules were analysed 6 times. The CRP 
concentration was measured by turbidimetry using a Hitachi 917 measuring system and 
DAKO reagents.  
For both test temperatures there were 48 measurements, or 46 degrees of freedom for the 
linear regression. The slope of the CRP concentration as a function of time is significantly 
different from 0 when the absolute value of slope b divided by its uncertainty ub (|b/ub|) is 
larger than t0.05, 22 = 2.01. None of the slopes (CRP mass concentration versus time) was 
significantly different from 0 (at a 95 % confidence level). The uncertainty given for the long-
term stability corresponds to the maximum uncertainty due to instability that could be hidden 
by the measurement variation after a period of 6 months. The results indicate that the 
material is stable when stored at either -70 or -20 °C. It was decided to store the material at 
-70 °C, and the corresponding value of ults, rel was used for the calculation of the uncertainty. 
Table 6: Long-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty contribution ults, rel due to storage for 6 months at the specified 
temperature 
Temperature 
[°C] 
b 
[(mg/L)/month] |b/ub| 
ults, rel 
[%] 
-70 0.023 0.07 0.468 
-20 -0.038 1.20 0.461 
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6 Characterisation 
6.1 General principles 
The measurements were calibrated with the matrix certified reference material ERM-DA470 
(see Table 7) by value transfer procedures that minimise the effects of calibration curve 
fitting and matrix differences [8]. The methods used for transferring values are validated, well 
established routine methods based on turbidimetry and nephelometry. The laboratories used 
either of two different approaches, called the open and closed value transfer procedures. For 
both procedures, measurements were performed over 4 days, with independent 
reconstitution of the reference material and preparation of dilutions on each of the 4 days. All 
reconstitutions and dilutions were obtained by weighing. 
Table 7: Certified value and expanded uncertainty of CRP in the calibrant ERM-DA470 
Certified value1) 
[mg/L] 
UCRM2)  
[mg/L] Calibrant 
39.2 1.9 1st Intl. Std. CRP 85/506 
1) In the reconstituted material. The certified value is the unweighted mean of 3 accepted mean 
values, independently obtained by 3 laboratories.  
2) The certified expanded uncertainty is the half-width of the 95 % confidence interval of the mean 
defined in footnote 1).  
In the open value transfer procedure 6 dilutions of ERM-DA470 were used for calibrating the 
instrument, and 6 dilutions of ERM-DA472/IFCC were assayed against this calibration. This 
procedure makes it possible to check for equivalent analytical responses of the materials (in 
the assays for which they are intended to be used) by assessing the linearity and the 
intercept of the regression line, as these are indicators for different matrix effects in the two 
materials. 
The open transfer procedure was optimised separately for each platform participating in the 
value assignment. The dilution scheme was optimised taking into account that dilutions done 
by the platforms should be avoided as much as possible (as these dilutions can not be 
corrected by more accurate weighings). On most measurement systems the option exists to 
provide 'pre-diluted' samples to the instrument, and to switch off the dilutions normally done 
by the platforms. Further it was required that the interval of concentrations for the dilutions of 
the calibrant was at least 10 % broader than the expected concentration interval of the 
dilutions of the candidate reference material at the high and low end of this expected 
concentration interval. Finally it had also to be taken into account that for each material all 6 
dilutions should be prepared from a single vial or ampoule.  
In the closed procedure 6 dilutions of ERM-DA470 and 6 dilutions of ERM-DA472/IFCC were 
assayed against the calibrants normally used by the laboratories. These calibrants mostly 
have values traceable to ERM-DA470. This procedure has in principle the disadvantage that 
the precision is lower, and that the proportionality of the materials can not be assessed 
directly. The presence of a matrix effect in either material may lead to non-linearity of the 
regression line, and/or to an intercept different from 0. Here again the dilution scheme was 
optimised for the two platforms, taking into account the working interval of the assays, the 
requirement that all dilutions should be prepared from a single vial, and that the volumes of 
the dilutions need to be large enough to allow for all the measurements.  
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6.2 Performance of the characterisation measurements 
The characterisation measurements were done in parallel with those for the certification of 12 
proteins in ERM-DA470k/IFCC. 
The laboratories were provided with detailed protocols and reporting sheets, as well as with 
vials of ERM-DA470 and ERM-DA472/IFCC. Laboratories were asked to specify the platform 
and reagents used, and the order in which the measurements were performed. Both 
procedures required that the ERM-DA470 was reconstituted the day before the 
measurements, according to the procedure described in the certificate of ERM-DA470 [5]. 
For each of the 4 measurement days a new vial of the ERM-DA470 was reconstituted and a 
new set of 6 dilutions of ERM-DA470 and ERM-DA472/IFCC prepared. 
Open value transfer procedure 
On each measurement day, 3 runs were performed. Each run was done with new 
calibrations using 6 dilutions of ERM-DA470. The 6 dilutions of ERM-DA472/IFCC and the 
control material (which consisted of a separate dilution of ERM-DA470) were measured as 
samples. Each calibrant, target and control material dilution was measured in duplicate at 
each run. Laboratory 1 used a different validated procedure. According to its procedure all 
the dilutions are measured in triplicate in each run, over 3 days, resulting in a slightly higher 
number of measurements. 
Closed value transfer procedure 
On each measurement day each of the 6 dilutions of ERM-DA470 and 6 dilutions of ERM-
DA472/IFCC were measured in triplicate. The laboratories used the dilution scheme given 
below. The intended volume fractions of the candidate reference material and the calibrant in 
the dilution schemes are given as percent of the reconstituted material present in the 
dilutions. 
Dilutions: 40, 50, 60, 70, 80 % of the reconstituted material, as well as the undiluted material. 
6.3 Data analysis 
Principle of the analysis 
The aim of the value transfer is to determine the transfer factor (TF) 
TF = CT/CR (1) 
where CT and CR are the mass concentration of CRP in the target material (T, ERM-
DA472/IFCC) and in the calibrant (RM, ERM-DA470), respectively.  
Six different dilutions of the calibrant are prepared. The mass concentration for CRP in each 
dilution will be: 
CR(i) = FR(i) x CR  (2) 
where FR is the dilution factor of the RM and (i) denotes the different dilutions (i = 1 to 6). 
The concentrations of CRP in the dilutions of the target material will be: 
CS(j) = FT(j) x CT (3) 
Where FT is the dilution factor of T and (j) denotes the different dilutions of T (j = 1 to 6). 
For the open value transfer procedure a calibration run is made, and the calibration curve is 
constructed by plotting the signals against the different dilutions of the calibrant. In a 
measurement run the different dilutions of T are assayed. The signals of these unknown test 
samples CS(j) are interpolated on the calibration curve, and are measured in relative 
concentrations of the calibrant: 
CS(j) = FR(j) x CR (4) 
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A combination of (3) and (4) gives: 
CS(j) = FT(j) x CT = FR(j) x CR 
FR(j) = (CT/CR) x FT(j) (5) 
which is the equation for a straight line through the origin (y = TF x). 
The different dilution factors FR(j) obtained by interpolation are plotted against the different 
dilution factors FT(j) used for the initial dilution of T. Since all dilutions are controlled by 
weighing, the uncertainty of FT(j) is negligible compared to that of the measurement results. 
For the closed value transfer procedure the dilutions of the RM can not be used directly to 
calibrate the platform. When the measured signals for the target material  
CS,T(j) = FT(j) x CT  
and for the RM  
CS, R(i) = FR(i) x CR  
are plotted against the dilutions FT(j) and FR(i) respectively, the TF = CT / CR can be derived 
as the ratio of the slopes of the respective linear regressions.  
Calculation of the dilutions 
The liquids used for the reconstitution of the materials and for the preparation of the dilutions 
were weighed to a standard deviation of maximum 0.0001 g. 
The following mass corrections were applied: 
For the reconstitution: 
iM,
intended
iM, m
mf =  
Where mintended is the mass intended to be added (1.0000 g), and mM,i is the measured mass 
of the water added to the vial 
In the case of predilutions: 
iPD,iPR,
iPR,
iP, mm
m
f +=  
where mPR,i and mPD,i are the masses of the of the reconstituted material and of the diluent for 
the predilution 
For the dilutions:  
iDD,iDM,
iDM,
ijD, mm
m
f +=  
for the dilution j of the material i, with mDM,i the mass of the reconstituted (eventually 
prediluted) material, and mDD,i the mass of the diluent for dilution j. 
The concentration cij (with c = m / V (mass / volume) and the unit g/L) of CRP in the dilutions 
is calculated via: 
cij = c0i x fM,i x fP,i x fD,ij  
with c0i the concentration of CRP in material i, and cij the concentration of CRP in dilution j of 
material i. 
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Determination of the transfer factors (TFs) 
For the open value transfer procedure the laboratories used the dilutions to construct the 
calibration curve directly. The values entered into their instrument for the concentrations of 
these dilutions were the values of the concentrations relative to the concentrations in ERM-
DA470, expressed in percent. These relative concentrations were calculated from the 
masses of the solutions (and predilution if relevant).  
Then for each run, the laboratories measured the dilutions of the target material in duplicate. 
The measured values Sijk (signal of the kth measurement of material i within dilution j) were 
plotted in scatter plots Sijk = f(cij) so as to evaluate outliers. Outliers were only rejected if 
there was a technical reason for doing so (a transcription error, wrong dilution, etc.). A linear 
regression with intercept was performed on the means of the Sijk in function of the 
concentration cij.  
The following specific acceptance criteria were applied for the open procedure: 
The mean control value (measured concentration of CRP in a control dilution of ERM-
DA470 relative to the concentration in the control sample expected on the basis of the 
dilution, calculated from the mass values obtained by weighing) is within 1.00 ± 0.05 
For the closed value transfer procedure the laboratories measured the 6 dilutions of the 
target (Y1-Y6) and the reference material (X1-X6) in triplicate on each day. For both the 
reference and the target materials, single measurement results Sijk (signal of the kth 
measurement of material i within dilution j, in g/L) were plotted in scatter plots Sijk = f(cij) so 
as to evaluate outliers. For both the reference and the target material, a linear regression 
with intercept was performed on the means of the Sijk in function of the concentration cij. 
The following analyses were performed on all data: 
- evaluation of the studentised residuals for the identification of outliers  
- testing for the homoscedasticity of the residuals (whether the variances are 
homogeneous) via a t-test 
- testing for normality (visual inspection and normal probability plot) 
- testing for linearity (visual inspection and evaluation of R2)  
- testing for outliers of the regression model according to the method of Lund [11]  
- verification that the intercept ± 4 times the standard deviation covers the origin.  
The TFs were calculated as the slope of the linear regression line for the open value transfer 
procedure, and as the ratio of the slopes of the linear regression lines for the candidate 
reference material and for the calibrant for the closed value transfer procedure.  
The following general acceptance criteria were applied to the datasets: 
1. The 95 % confidence intervals of the intercepts of the regressions of the calibrant 
and the target materials must be overlapping (closed procedure only). 
2. R2 of the regression must be above 0.97 for Immage data and above 0.98 for all 
other measurement systems 
3. Data from at least 4 dilutions must be available 
4. The completeness of data must be at least 50 % for the data of a particular day. 
Otherwise the data from that day are declared non-valid 
5. At least two daily value assignments must be valid 
6. The day-to-day variation (RSD) of valid datasets for a particular laboratory must 
be equal to or below 5 %  
Rationale for the acceptance criteria (see also reference [8]): 
- Non-overlapping confidence intervals of the intercepts of closed protocol regressions are 
either an indication of differing matrix effects or of quality problems of measurements 
resulting in scattering, both of which would result in non-valid TFs. 
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- Overall R2 < 0.98 of regression indicates quality problems in the measurements (scattering, 
outliers, run-to-run variation). Laboratory 5 worked with an instrument with higher scattering 
of the data. Therefore the threshold for this laboratory was reduced to 0.97.  
- On the basis of criteria 3, 4, 5, and 6, datasets with general quality problems were 
excluded. 
6.4 Results of the characterisation measurements 
6.4.1 General considerations 
The measurements were performed by 8 laboratories. Of these laboratories 6 used an open 
value transfer procedure and 2 a closed value transfer procedure (Table 8). They are coded 
from laboratory 1 to 8. 
The requirement that all the dilutions are prepared from a single vial made the volumes of the 
dilutions available small, and required the optimisation of the dilution scheme for the different 
platforms, depending on their sample intake. One of the possible problems was the 
evaporation of samples, which can become significant when small sample volumes are used, 
and when the samples are stored on the platform for a long time before they are measured 
(as is the case with slower platforms and when many proteins are measured). This problem 
was avoided in different ways, for example by measuring fewer proteins per series of 
dilutions, or capping the samples between measurements. The dilutions have been 
measured in different orders by different laboratories, and some laboratories have measured 
in different orders on different days. Overall no significant differences were detected between 
laboratories running the samples in different orders.  
6.4.2 Scrutiny of the data 
For all 8 laboratories valid datasets were obtained. Data measured on day 1 by laboratory 6 
were not valid because for technical reasons less than 50 % of the measurements had been 
done (criterion 4). Laboratory 5 only performed three measurement sets, and data measured 
on day 2 by laboratory 5 was not valid because the R2 of the regression was below 0.97 
(criterion 2). Data from laboratory 7 measured on day 1 were excluded because of non-
overlapping confidence intervals of the intercepts (criterion 1). 
Table 8 gives the average transfer factors for each laboratory, and Figure 3 shows the 
results of the characterisation study.  
 
Table 8: Summary of the measurements performed by the participating laboratories   
Laboratory/ 
procedure 
used 
Platform TF 
L1/ open AU640 1.055 
L2/ open BN II 1.044 
L3/ open Hitachi 917 0.9939 
L4/ open Hitachi 917 1.076 
L5/ closed Immage 1.159 
L6/ open Architect  1.073 
L7/ closed Hitachi 919 1.053 
L8/ open Hitachi 917 1.073 
 
The individual daily measured values are normally distributed at α = 0.05 (error probability 
upon rejection of the zero hypothesis). The lab means distribution is not normally distributed 
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at an α = 0.05 (K-crit = 3.7, K=3.74) according to a Kurtosis test, but is at α = 0.01. The 
skewness test indicates normality at α = 0.05. Laboratory 5 is an outlier at α = 0.05 when the 
data are evaluated either with the Dixon's test or Nalimov t-test. However, the estimated 
expanded uncertainty of the result of laboratory 5 covers the mean of laboratory means. 
Therefore Laboratory 5 was retained in the analysis. 
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Figure 3: Results of the characterisation measurements for CRP. The bars represent the 
laboratory means ± 2s. The dotted line represents the mean of means, and the bars at the 
beginning and the end of the dotted line represents the mean of means ± 2s. 
 
 
 
Table 9: Mean of means and relative standard deviation of the TFs, calculated using all valid 
results 
TF 
Mean of means srel [%] 
1.066 4.32 
 
 
 
 
 24 
 
7 Uncertainty budget and certified value  
7.1 Estimation of the uncertainty 
The certified uncertainties consist of the relative standard uncertainty related to 
characterisation (uchar, rel), the relative standard uncertainty of the calibrant (ucal, rel), and the 
uncertainties due to the between-bottle heterogeneity (ubb, rel), and possible degradation 
during long-term storage (ults, rel) [12]. 
• uchar, rel was estimated as the relative standard uncertainty of the mean of laboratory 
means, i.e. s/(p)0.5 with s the relative standard deviation of the mean of laboratory means 
and p the number of datasets, converted into a relative value 
• ucal, rel was estimated as half of the half-width of the 95 % confidence interval of the 
certified value of CRP in the calibrant, ERM-DA470, relative to the certified value. 
• ubb, rel was taken as the sbb, rel as defined in Section 4.1.  
• ults, rel was estimated from stability tests and were taken from Table 6 (6 months stability 
study). 
The relative combined standard uncertainty was calculated as the square root of the sum of 
squares of the individual contributions, according to: 
2
rel lts,
2
rel bb,
2
rel cal,
2
rel char,rel c, uuuuu +++=   
The various uncertainty contributions and the relative combined standard uncertainty (uc, rel) 
are shown in Table 10. 
 
Table 10: Uncertainty budget for ERM-DA472/IFCC 
uchar, rel 
[%] 
ucal, rel 
[%] 
ubb, rel 
[%] 
ults, rel 
[%] 
uc, rel 
[%] 
1.53 2.42 0.29 0.47 2.92 
 
7.2 Certified value 
The certified value (Table 11) was calculated from the TF (Table 9) and the certified value in 
ERM-DA470 (Table 6) according to: 
DA470ERMDA472ERM TF −− ⋅= cc  
The relative expanded uncertainty was calculated from the relative combined standard 
uncertainty uc, rel (Table 10) by multiplication with a coverage factor k. This coverage factor 
was taken as 2. The relative expanded uncertainty was multiplied with the mean of dataset 
means to obtain the expanded uncertainty UCRM.  
 
Table 11: Certified value and expanded uncertainty for the mass concentration of CRP in ERM-
DA472/IFCC 
Certified value 
[mg/L] 
UCRM (k = 2) 
[mg/L] 
41.8 2.5 
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8 Metrological traceability 
The measurements of CRP were calibrated with ERM-DA470 applying the two value transfer 
procedures as described in the report. The value transfer measurements were strictly 
controlled with respect to the adherence to the procedure and the adequate functioning of 
equipment and reagents verified. The methods used were all immunochemical. Different 
combinations of reagents and platforms were used, and gave consistent results. Therefore 
the results are not dependent on the individual measurement procedures. 
The value assignment measurements of CRP in ERM-DA470 had been calibrated with the 
1st International Standard CRP 85/506, to which values had been assigned by a using a pure 
protein as calibrant, also using immunochemical methods and a collaborative study [5]. 
Therefore ERM-DA472 is traceable to the pure protein calibrant, and thus to the SI, applying 
the procedures described in the present report and in the report for ERM-DA470 [5], using 
immunochemical methods.  
 
9 Commutability 
During the value assignment process it was found that, as was the case for ERM-DA470, 
there were no significant matrix effects (closed protocol) or differences in matrix effect 
between the CRM and ERM-DA470 (open protocol). This was done by verifying that the 
regression line of the signal measured for the CRP concentrations in the dilutions in function 
of the volume fraction of the certified reference material in the dilutions was linear, and 
passed through the origin. Also, the following combinations of platforms and reagents 
produced consistent results: 
 
- Abbott Architect, Abbott reagents 
- Beckman Immage, Beckman reagents 
- BN II, Dade Behring reagents 
- Hitachi 917, DAKO reagents 
- Hitachi 917, Roche reagents 
- Hitachi 919, Nitto Boseki reagents 
- AU640, Olympus reagents 
 
The commutability of the material has to be demonstrated for each particular assay. 
However, the results of external quality assessment schemes show that the inter-assay 
variation of CRP certified has generally been significantly reduced during the long-term use 
of ERM-DA470 [6], [7]. As this is a strong indication of commutability, ERM-DA472/IFCC was 
produced in a similar manner up until the point where the materials were either ampouled 
(this material), or filled in vials and lyophilised (ERM-DA470).  
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10 Intended use and instructions for use 
The material is primarily intended to be used to calibrate serum-based protein standards and 
control materials of organisations which offer such preparations for the quantification of CRP 
by immunoassay. 
When the material is used as a calibrant in a particular assay the commutability should be 
verified for the assay concerned.  
To make it ready for use, the content of the ampoule has to be thawed in a water-bath at 
room temperature, while gently rotating the ampoule so as to mix the contents every 5-10 
minutes, until the serum is thawed.  
 
The minimum sample intake for which the material was shown to be homogenous was 20 μL, 
but it can be expected to be homogenous at nL levels, as it is a true solution 
 
Storage 
Unopened ampoules should be stored at temperatures at or below -20 °C. Under the 
condition that any microbial contamination during the reconstitution procedure has been 
excluded, the solution of ERM-DA472/IFCC can be used for one week, as it was verified that 
changes to the certified concentration observed during that period are not significant. After 
the opening of the ampoule it is advisable to store the material at 2 to 8 °C in a sealed 
container.  
However, the European Commission cannot be held responsible for changes that happen 
during storage of the material at the customer's premises, especially of opened ampoules. 
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